Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Core Insights - Johnson & Johnson announced promising results from a Phase 1b study of JNJ-90014496, a dual-targeting CAR T-cell therapy for relapsed or refractory large B-cell lymphoma, showing a 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose [1][2] Company Overview - Johnson & Johnson is committed to advancing innovative therapies for patients with B-cell malignancies, emphasizing their long-term dedication to addressing unmet medical needs [2][4] - The company is expanding its pipeline of CAR T therapies through a collaboration with AbelZeta Inc. to develop next-generation CAR T-cell therapies [2][3] Industry Context - Large B-cell lymphoma, particularly diffuse large B-cell lymphoma, accounts for approximately 40% of all non-Hodgkin lymphoma cases globally, with an estimated 150,000 new cases diagnosed each year [3] - Current single-antigen-targeting CD19 CAR T therapies provide long-term remissions for only about 40% of patients, highlighting the need for innovative treatment options [2][3]